Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|PX-866||Sonolisib|PX866||PI3K Inhibitor (Pan) 40||Sonolisib (PX-866) is a PI3K inhibitor, which inhibits the activation of the PI3K/Akt signaling pathway, thereby inhibiting cancer cell motility and growth (PMID: 17766839).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|PIK3CA mutant||Advanced Solid Tumor||sensitive||PX-866||Phase I||Actionable||In a Phase I trial, PX-866 demonstrated efficacy and was well tolerated in patients with advanced solid tumor with both PIK3CA wild-type and mutant status (PMID: 22693357).||22693357|
|PTEN del||prostate cancer||not predictive||PX-866||Phase II||Actionable||In a Phase II trial, Sonolisib (PX-866) treatment resulted in stable disease as best response in 66.7% (2/3) of patients with recurrent or metastatic castration-resistant prostate cancer harboring homozygous PTEN deletion, while in PTEN wild-type patients resulted in a partial response in 14.3% (2/14) and stable disease in 28.6% (4/14) of patients (PMID: 31056399).||31056399|
|PIK3CA wild-type||Advanced Solid Tumor||sensitive||PX-866||Phase I||Actionable||In a Phase I study, PX-866 demonstrated efficacy and was well tolerated in patients with advanced solid tumor with both PIK3CA wild-type and mutant status (PMID: 22693357).||22693357|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|